Drug Profile
GLPG 2737
Alternative Names: ABBV 2737; G 1117337; GLPG-2737Latest Information Update: 22 May 2023
Price :
$50
*
At a glance
- Originator Cystic Fibrosis Foundation Therapeutics; Galapagos NV
- Class Antifibrotics; Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autosomal dominant polycystic kidney disease; Cystic fibrosis
Most Recent Events
- 22 May 2023 Discontinued - Phase-I for Cystic fibrosis (Combination therapy) in Sweden, Serbia, Netherlands, Greece, Belgium, Bulgaria, United Kingdom (PO), prior to May 2023
- 22 May 2023 Discontinued - Phase-I for Cystic fibrosis (Combination therapy, In volunteers) in Belgium (PO), prior to May 2023
- 22 May 2023 Discontinued - Phase-I for Cystic fibrosis (In volunteers) in Netherlands (PO), prior to May 2023